In vitro activity of the new quinolone RO 23-6240 (AM-833) and the new cephalosporins RO 15-8074 and RO 19-5247 (T-2525) against Mycobacterium fortuitum and Mycobacterium chelonae.
D000583:Amikacin / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015281:Cefmenoxime / Q000031:analogs & derivatives*; D015296:Ceftizoxime / Q000031:analogs & derivatives*; D002511:Cephalosporins / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000494:pharmacology; D004338:Drug Combinations / Q000494:pharmacology; D016576:Fleroxacin; D009161:Mycobacterium / Q000187:drug effects*; D009170:Nontuberculous Mycobacteria / Q000187:drug effects*; D013420:Sulfamethoxazole / Q000494:pharmacology; D014295:Trimethoprim / Q000494:pharmacology; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D004338:Drug Combinations; C047444:cefetamet; D002939:Ciprofloxacin; C049493:cefteram; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D000583:Amikacin; D014295:Trimethoprim; D015296:Ceftizoxime; D013420:Sulfamethoxazole; D015281:Cefmenoxime; D016576:Fleroxacin